Felzartamab

Summary

Felzartamab (CHEMBL4594579) is a phase-3 clinical-stage antibody; indicated across 7 conditions including plasma cell myeloma and glomerulonephritis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 7 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594579
Name	Felzartamab
Type	Antibody
Max phase	3

Also known as: Felzartamab, MOR-03087, MOR-202, Mor03087, MOR03087, Mor202, TJ-202, TJ202, FELZARTAMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
glomerulonephritis	2	MONDO:0002462	MONDO:0002462
kidney disorder	2	MONDO:0005240	EFO:0003086
IgA glomerulonephritis	2	MONDO:0005342	EFO:0004194
membranous glomerulonephritis	1	MONDO:0005376	EFO:0004254
systemic lupus erythematosus	1	MONDO:0007915	MONDO:0007915
lupus nephritis	1	MONDO:0005556	EFO:0005761

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	4
PHASE1/PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06685757	PHASE3	RECRUITING	A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
NCT06935357	PHASE3	RECRUITING	A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06962800	PHASE3	RECRUITING	A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT07444489	PHASE3	ENROLLING_BY_INVITATION	A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
NCT07219043	PHASE2	RECRUITING	A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
NCT01421186	PHASE1/PHASE2	COMPLETED	A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
NCT03860038	PHASE2	COMPLETED	TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04145440	PHASE1/PHASE2	COMPLETED	Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
NCT04733040	PHASE2	COMPLETED	Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)
NCT04893096	PHASE2	COMPLETED	MOR202 for Refractory MN
NCT05021484	PHASE2	COMPLETED	Felzartamab in Late Antibody-Mediated Rejection
NCT05065970	PHASE2	COMPLETED	Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
NCT06064929	PHASE1	ACTIVE_NOT_RECRUITING	A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
NCT05140824	PHASE1	TERMINATED	A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).